Xl888

Manufactured by Selleck Chemicals

Sourced in Australia

The XL888 is a high-performance lab equipment designed for precise and reliable experimentation. It features advanced temperature control, precise measurement capabilities, and durable construction. The core function of the XL888 is to provide a controlled environment for scientific research and analysis.

Automatically generated - may contain errors

Lab products found in correlation

4 protocols using xl888

Antibodies and Inhibitors for Cancer Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against HSP70 (#4872), CRAF (#9244), HSP90 (#4874), SKP2 (#2652), p-Akt (Ser473) (#4060), Akt (#9272), ERK1/2 (#9102), p-MEK1/2 (#9121), MEK1/2 (#9122), MEK1 (#9124) and p-MEK1 (#9127) were purchased from Cell Signalling Technology (Beverly, MA). Antibodies against p-ERK1/2 (sc-7383), BRAF (sc-166), CDC37 (sc-1617 and sc-13129) and GAPDH (sc-32233) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The antibodies against Caspase-3 (AAP-113) were from Enzo Life Sciences (Dural, NSW, Australia). Antibody against BRAF^V600E (26039) was purchased from NewEast Biosciences (NewEast Biosciences, PA). The HSP90 inhibitors AUY922 and XL888, the MEK inhibitor AZD6244, the PI3K/Akt inhibitor LY294002 and the BRAF inhibitor PLX4720 were purchased from Selleckchem (Redfern, NSW, Australia).

Wang C.Y., Guo S.T., Wang J.Y., Yan X.G., Farrelly M., Zhang Y.Y., Liu F., Yari H., La T., Lei F.X., Jin L., Zhang X.D, & Jiang C.C. (2016). Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922. Oncotarget, 7(31), 49597-49610.

+ Open protocol

+ Expand

Comprehensive Signaling Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies used in this study were anti-B-RAF (D9T6S), anti-GFP, anti-HSP90, anti-p44/42 MAPK (ERK1/2), anti-phospho-p44/22 (ERK1/2) (Thr 202 /Tyr 204 ), anti-MEK1/2, anti-phospho-MEK1/2 (Ser 217/212 ), anti-AKT, anti-phospho-AKT (S473), anti-EGFR (D38B1), anti-phospho-EGFR (Tyr 1068 ) (D7A5) (all from Cell Signaling Technology), anti-RAF-B (F-7), anti-α-tubulin (Santa Cruz Biotechnology), anti-glyceraldehyde-3-phosphate dehydrogenase (Abcam), and anti-HA (3F10) (Roche Diagnostics). Belvarafenib (HM95573), dabrafenib, encorafenib, GDC-0879, lifirafenib (BGB-283), LY3009120, MLN2480, naporafenib (LXH254), sorafenib, TAK-632, trametinib, vemurafenib, and XL888 were purchased from SelleckChem. All inhibitors were dissolved in dimethyl sulfoxide (DMSO).

Lauinger M., Christen D., Klar R.F.U., Roubaty C., Heilig C.E., Stumpe M., Knox J.J., Radulovich N., Tamblyn L., Xie I.Y., Horak P., Forschner A., Bitzer M., Wittel U.A., Boerries M., Ball C.R., Heining C., Glimm H., Fröhlich M., Hübschmann D., Gallinger S., Fritsch R., Fröhling S., O'Kane G.M., Dengjel J, & Brummer T. (2023). BRAF^Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability. Science advances, 9(35).

+ Open protocol

+ Expand

Screening of HSP90 inhibitor compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following drugs were purchased from Selleck Chem: 17-AAG (Cat No: S1141), NMS-E973 (Cat No: S7282), Onalespib (Cat No: S1163), XL888 (Cat No: S7122), Alvespimycin (17-DMAG) HCl (Cat No: S1142), VER-49009 (Cat No: S7458), BIIB021 (Cat No: S1175), SNX-2112 (Cat No: S2639), and Anisomycin (S7409). Lysophosphatidic acid (LPA, L7260) was purchased from Sigma. All drugs were pre-arrayed into a 384-well source plate and serial dilutions were made in 100% DMSO. A fixed 100-nL volume was then transferred from the source plate to assay wells using a pin tool (Tecan). Screens were performed at 10 doses with two technical (on-plate) replicates. Each assay plate contained 16 DMSO-treated negative controls, 16 non-treated controls, and 16 Background (No Cells) controls.

Powell R.T., Moussalli M.J., Guo L., Bae G., Singh P., Stephan C., Shureiqi I, & Davies P.J. (2022). deepOrganoid: A brightfield cell viability model for screening matrix-embedded organoids. SLAS discovery : advancing life sciences R & D, 27(3).

+ Open protocol

+ Expand

Tanespimycin-Induced Proteome Changes

Check if the same lab product or an alternative is used in the 5 most similar protocols

HeLa cells were seeded at a density of 5 × 10⁶ cells into 150 mm culture dishes with 20 mL of SILAC DMEM medium containing either isotopically light L-lysine and L-arginine or isotopically heavy ¹³C₆¹⁵N₂-L-lysine and ¹³C₆-L-arginine (Silantes) and supplemented with 10% dialyzed FBS (Valley Biomedical Inc.) and 1 % pen./strep. (Fisher Scientific). Cells were treated with various concentrations (100, 250, 500, 1000 nM) Tanespimycin (17-N-allylamino-17-demethoxygeldanamycin [17-AAG] Cayman Chemicals), 300 nM XL888 (Selleckchem), 400 μM Novobiocin (Sigma) or 0.1% v/v dimethyl sulfoxide (DMSO) for 18 h before harvesting with 5 mL of phosphate buffered saline (PBS) containing 5 mM EDTA. Cells were washed with PBS and pelleted by centrifugation at 300 g for 3 min and suspended in 170 mM Na₂HPO₄ pH 8.0 for chemical cross-linking.

Chavez J.D., Schweppe D.K., Eng J.K, & Bruce J.E. (2016). In vivo conformational dynamics of Hsp90 and its interactors. Cell chemical biology, 23(6), 716-726.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!